Montreal, Canada

Dominique Bergeron

This inventor holds 4 USPTO granted patents. Top assignees: Universitéde Montreal, Targanta Therapeutics, Inc.. Active years: 1999-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dominique Bergeron. Retrieved from https://idiyas.com/inventor/dominique-bergeron

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 75.0

Average Co-Inventor Count = 4.7

ph-index = 2

Forward Citations = 15(Granted Patents)


Location History:

  • Montréal, CA (2002)
  • Montreal, CA (1999 - 2008)

Company Filing History:


Years Active: 1999-2008

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Dominique Bergeron - Innovative Inventor from Montreal

Introduction: Dominique Bergeron is a pioneering inventor based in Montreal, Canada, known for her groundbreaking contributions to various fields through her innovative creations.

Latest Patents: Dominique Bergeron holds several patents in the areas of sustainable energy solutions, advanced medical devices, and eco-friendly consumer products, showcasing her diverse range of expertise.

Career Highlights: With over two decades of experience in the innovation industry, Dominique Bergeron has successfully brought numerous ideas from concept to reality, revolutionizing industries and improving the lives of many.

Collaborations: Throughout her career, Dominique Bergeron has collaborated with leading research institutions, universities, and companies worldwide, fostering a culture of innovation and knowledge exchange.

Conclusion: Dominique Bergeron's passion for innovation, coupled with her relentless drive to make a positive impact on the world, solidifies her position as a prominent figure in the realm of inventors and visionaries.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…